Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective studyJingjing Wu, Mingzhi Zhang, Jieming Zhang et al.|Investigational New Drugs|2022Cited by 44
<scp>MYC</scp> overexpression but not <scp>MYC</scp>/<scp>BCL2</scp> double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patientsYanjie Wang, Qingjiang Chen, Donglin Liu et al.|Cancer Medicine|2023Cited by 6
A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)Xudong Zhang, Mingzhi Zhang, Wenhua Wang et al.|Blood|2022Cited by 4
Clinical features and prognosis of chronic natural killer cell lymphoproliferative disordersDonglin Liu, Xudong Zhang, Yanjie Wang et al.|Research Square|2023Cited by 0